natgillin/translations-raw huggingface dataset:
In patients with HBeAg negative CHB (pre-core mutant), without cirrhosis, treatment should be administered at least until HBs seroconversion or there is evidence of loss of efficacy.
U HBeAg negativnih bolesnika s kroničnim hepatitisom B ("divlji tip" virusa), a bez ciroze, liječenje treba provoditi najmanje do serokonverzije HBs ili do dokazanog gubitka djelotvornosti.
In patients with HBeAg positive chronic hepatitis B (CHB) without cirrhosis, treatment should be administered for at least 6-12 months after HBeAg seroconversion (HBeAg and HBV DNA loss with HBeAb detection) is confirmed, to limit the risk of virological relapse, or until HBsAg seroconversion or there is loss of efficacy (see section 4.4).
U HBeAg pozitivnih bolesnika s kroničnim hepatitisom B, a bez ciroze, liječenje treba provoditi najmanje 6 - 12 mjeseci nakon potvrđene serokonverzije HBeAg (gubitak HBeAg i HBV DNK uz pojavu HBeAb), kako bi se ograničio rizik od relapsa virusa, odnosno do serokonverzije HBsAg ili do gubitka djelotvornosti (vidjeti dio 4.4).
In patients with HCV genotype 1a with a baseline Q80K amino acid substitution an emerging R155K substitution was observed most frequently at failure.
U bolesnika s HCV genotipom 1a s početnom Q80K supstitucijom aminokiselina pri neuspjehu liječenja najčešće je bila uočena nastala R155K supstitucija.
In patients with HCV RNA between 100 IU/ml and 1,000 IU/ml at week 12, 2/8 (25%) achieved an SVR.
Od bolesnika s koncentracijom HCV RNK između 100 IU/ml i 1000 IU/ml u 12. tjednu trajni virološki odgovor postiglo je 2/8 (25%) bolesnika.
in patients with hepatic impairment when inducers or inhibitors of CYP3A4 are concurrently administered and after their discontinuation (see section 4.5) and/or if ciclosporin dosing is markedly reduced or discontinued, as these populations are most likely to have special dosing requirements.
u bolesnika s oštećenjem jetre prilikom istodobne primjene induktora ili inhibitora CYP3A4 i nakon njihovog ukidanja (vidjeti dio 4.5); i/ili ako je doziranje ciklosporina značajno smanjeno ili je davanje prekinuto, budući da je u ove skupine najvjerojatnije potrebno posebno prilagoditi doziranje.
In patients with hepatic impairment, exposures were elevated by 9 to 25%.
U bolesnika s oštećenjem funkcije jetre izloženost je bila veća za 9 do 25%.
In patients with heterozygous familial hypercholesterolemia (HeFH) on high dose statin, the systemic exposure of evolocumab was slightly lower than in subjects on low-to-moderate dose statin (the ratio of AUClast 0.74 [90%CI 0.29 ; 1.9]).
U bolesnika s heterozigotnom obiteljskom hiperkolesterolemijom na visokim dozama statina, sistemska izloženost evolokumabu je bila nešto manja nego u ispitanika na niskim do umjerenim dozama statina (omjer AUClast 0,74 [90% CI 0,29 ; 1,9]).
In patients with heterozygous familial hypercholesterolemia (HeFH) on high dose statin, the systemic exposure of evolocumab was slightly lower than in subjects on low-to-moderate dose statin (the ratio of AUClast 0.74 [90%CI 0.29 ; 1.9]).
U bolesnika s heterozigotnom obiteljskom hiperkolesterolemijom na visokim dozama statina, sistemska izloženost evolokumabu je bila nešto manja nego u ispitanika na niskim do umjerenim dozama statina (omjer AUClast 0,74 [90% CI 0,29; 1,9]).
In patients with hidradenitis suppurativa, a dose of 160 mg Humira on Week 0 followed by 80 mg on Week 2 achieved serum adalimumab trough concentrations of approximately 7 to 8 μg/mL at Week 2 and Week 4.
Nakon primjene lijeka Humira u dozi od 160 mg u nultom tjednu i 80 mg u 2. tjednu u bolesnika s gnojnim hidradenitisom, najniže koncentracije adalimumaba u serumu u 2. i 4. tjednu iznosile su približno 7 do 8 µg/ml.
In patients with high blood pressure and type 2 diabetes, 300 mg (four tablets a day) once daily is the preferred maintenance dose for the treatment of associated kidney disease.
U bolesnika koji imaju visoki krvni tlak i boluju od šećerne bolesti tipa 2 preporučena doza održavanja za liječenje pridružene bolesti bubrega iznosi 300 mg jednom na dan (četiri tablete na dan).
In patients with high blood pressure and type 2 diabetes, 300 mg (two tablets a day) once daily is the preferred maintenance dose for the treatment of associated kidney disease.
U bolesnika koji imaju visoki krvni tlak i boluju od šećerne bolesti tipa 2 preporučena doza održavanja za liječenje pridružene bolesti bubrega iznosi 300 mg (dvijetablete na dan) jedanput na dan.
In patients with high blood pressure and type 2 diabetes, 300 mg (two tablets a day) once daily is the preferred maintenance dose for the treatment of associated kidney disease.
U bolesnika koji imaju visoki krvni tlak i boluju od šećerne bolesti tipa 2 preporučena doza održavanja za liječenje pridružene bolesti bubrega iznosi 300 mg jednom na dan (dvije tablete na dan).
In patients with high blood pressure and type 2 diabetes, 300 mg once daily is the preferred maintenance dose for the treatment of associated kidney disease.
U bolesnika koji imaju visoki krvni tlak i boluju od šećerne bolesti tipa 2 preporučena doza održavanja za liječenje pridružene bolesti bubrega iznosi 300 mg jednom na dan.
In patients with high levels of inhibitor, factor IX therapy may not be effective and other therapeutic options should be considered.
U pacijenata s visokom razinom inhibitora liječenje faktorom IX može biti neučinkovito i potrebno je razmotriti druge mogućnosti liječenja.
In patients with high levels of inhibitor, factor VIII substitution therapy may not be effective and other therapeutic options should be considered.
U bolesnika s visokim razinama inhibitora, nadomjesna terapija faktorom VIII može biti neučinkovita te je potrebno razmotriti druge terapijske opcije.
In patients with high levels of inhibitor, factor VIII therapy may not be effective and other therapeutic options should be considered.
U bolesnika s visokim razinama inhibitora liječenje faktorom VIII može biti nedjelotvorno pa treba razmotriti druge terapijske opcije.
In patients with high levels of inhibitor, factor VIII therapy may not be effective and other therapeutic options should be considered.
U bolesnika s visokim razinama inhibitora liječenje primjenom faktora VIII možda neće biti djelotvorno pa treba uzeti u obzir druge mogućnosti liječenja.
In patients with high levels of inhibitor, factor VIII therapy may not be effective and other therapeutic options, such as immune tolerance induction (ITI), should be considered.
U bolesnika s visokom razinom inhibitora liječenje faktorom VIII možda neće biti učinkovito i stoga će biti potrebno razmotriti druge mogućnosti liječenja kao što je indukcija imunološke tolerancije.
In patients with high titres of inhibitor, factor VIII therapy may not be effective and other therapeutic options should be considered.
U bolesnika s visokim titrima inhibitora iznad 10 BU, terapija faktorom VIII ne mora biti učinkovita i potrebno je razmotriti druge terapijske mogućnosti.
In patients with high tumour burden, corresponding figures were 16/81 (20%) and 2/28 (7%) (see section 4.4).
U bolesnika s velikim opterećenjem tumorskom masom te brojke iznosile su 16/81 (20%) i 2/28 (7%) (vidjeti dio 4.4).
In patients with high viral load (> 100,000 copies/ml) choice of therapy needs special consideration (see section 5.1).
Potrebna je posebna pažnja pri razmatranju odabira terapije u bolesnika s visokim virusnim opterećenjem (> 100 000 kopija/ml) (vidjeti dio 5.1).
In patients with HIT, symptoms such as arterial and venous thrombosis, disseminated intravascular coagulation (DIC), purpura, petechiae and gastrointestinal bleeding (melena), may occur.
Kod pacijenata s HIT-om mogu se javiti simptomi poput arterijske i venske tromboze, diseminirane intravaskularne koagulacije (DIK), purpure, petehije i gastrointestinalna krvarenja (melena).
In patients with HIV
Bolesnici s HIV infekcijom
In patients with HIV infection For reversal of neutropenia
Bolesnici s HIV-infekcijom Za obrat neutropenije
In patients with HIV infection, cases of pancreatitis and peripheral neuropathy (or paresthesia) have been reported.
U bolesnika zaraženih HIV-om, zabilježeni su slučajevi pankreatitisa i periferne neuropatije (ili parestezije).
In patients with hypergammaglobulinemia, normalization of IgG levels was observed by Week 52 in 49% and 20% of patients receiving Benlysta and placebo, respectively.
U bolesnika s hipergama- globulinemijom, normalizacija razine IgG bila je do 52. tjedna opažena u 49% bolesnika koji su primali lijek Benlysta, te u 20% bolesnika koji su primali placebo.
In patients with imatinib-resistant or intolerant CML in chronic phase and accelerated phase The data described below reflect exposure to Tasigna in 458 patients in an open-label multicentre Phase II study in patients with imatinib-resistant or intolerant CML in chronic phase (n=321) and accelerated phase (n=137) treated at the recommended dose of 400 mg twice daily.
Bolesnici s KML-om u kroničnoj i ubrzanoj fazi s rezistencijom ili intolerancijom na imatinib Podaci prikazani u nastavku odražavaju izloženost Tasigni u 458 bolesnika u otvorenom multicentričnom ispitivanju faze II u bolesnika s KML-om u kroničnoj (n=321) i ubrzanoj fazi (n=137) s rezistencijom ili intolerancijom na imatinib, a koji su liječeni preporučenom dozom od 400 mg dva puta na dan.
In patients with impaired hepatic function, atosiban should be used with caution (see sections 4.2 and 4.4).
U bolesnika s oštećenjem jetre atosiban treba primjenjivati s oprezom (vidjeti dio 4.2 i 5.2).
In patients with impaired liver function, lactate clearance may be restricted.
U bolesnika s oštećenjem jetrene funkcije klirens laktata može biti ograničen.
In patients with impaired renal function (stages 2 to 4 according to the international classification of chronic kidney disease, i.e. creatinine clearance between 15 and 89 ml/min), Cmax and AUC tended to be increased by a factor of 2.5 without any impact on half-life (see section 4.2).
Kod bolesnika s oštećenom funkcijom bubrega (od 2. do 4. stupnja prema međunarodnoj klasifikaciji kroničnih bolesti bubrega, odnosno klirens kreatinina između 15 i 89 ml/min), Cmax i AUC pokazuju tendenciju povećanja za faktor od 2,5 bez ikakvog utjecaja na poluvijek (vidjeti dio 4.2).
In patients with impaired renal function, imatinib plasma exposure seems to be higher than that in patients with normal renal function, probably due to an elevated plasma level of alpha-acid glycoprotein (AGP), an imatinib-binding protein, in these patients.
Izloženost imatinibu u palzmi je izgleda viša kod bolesnika s oštećenom funkcijom bubrega, vjerojatno zbog povišene razine alfa-kiselog glikoproteina (AGP) u plazmi, proteina koji veže imatinib, u tih bolesnika.
In patients with known bone marrow infiltrating infections or malignancy, consider appropriate therapy for treatment of the underlying condition, in addition to administration of filgrastim for treatment of neutropenia.
U bolesnika s poznatom infiltracijom uzročnicima infekcije ili zloćudnom bolešću valja, povrh primjene filgrastima za korekciju leukopenije, razmotriri i primjenu prikladnog lijeka za liječenje stanja u podlozi.
In patients with known bone marrow-infiltrating infections or malignancy, consider appropriate therapy for treatment of the underlying condition in addition to administration of filgrastim for treatment of neutropenia.
U bolesnika u kojih se potvrdi da je infekcija ili zloćudna bolest infiltrirala koštanu srž treba razmotriti odgovarajuću terapiju za liječenje osnovne bolesti uz primjenu filgrastima zbog liječenja neutropenije.
In patients with known complete absence of dihydropyrimidine dehydrogenase (DPD) activity (see section 4.4),
Bolesnici s poznatim potpunim nedostatkom aktivnosti dihidropirimidin dehidrogenaze (DPD) (vidjeti dio 4.4),
In patients with known dihydropyrimidine dehydrogenase (DPD) deficiency (see section 4.4).
Bolesnici s poznatim deficitom dihidropirimidin dehidrogenaze (DPD) (vidjeti dio 4.4).
In patients with known predisposing risk factors for iritis/uveitis, travoprost can be used with caution.
U bolesnika s poznatim predisponirajućim rizičnim faktorima za iritis/uveitis, travoprost se može koristiti s oprezom.
In patients with liver scarring, Viekirax treatment in combination with dasabuvir and ribavirin resulted in a clearance rate of between 93% and 100% after 24 weeks of treatment.
U bolesnika s ožiljcima na jetri, terapija lijekom Viekirax u kombinaciji s dasabuvirom i ribavirinom rezultirala je stopom čišćenja između 93% i 100% nakon 24 tjedana terapije.
In patients with long-term stable angina, Corlentor was more effective than placebo at improving exercise capacity and was as effective as atenolol and amlodipine.
U bolesnika s kroničnom stabilnom anginom, Corlentor je bio učinkovitiji od placeba prilikom poboljšavanja kapaciteta za vježbanje, te je bio podjednako učinkovit kao atenolol i amlodipin.
In patients with long-term stable angina, Procoralan was more effective than placebo at improving exercise capacity and was as effective as atenolol and amlodipine.
U bolesnika s kroničnom stabilnom anginom, Procoralan je bio učinkovitiji od placeba prilikom poboljšavanja kapaciteta za vježbanje, te je bio podjednako učinkovit kao atenolol i amlodipin.
In patients with low albumin levels (≤ 35 g/L) or MELD score ≥ 10 at baseline, there was a three-fold greater risk of hepatic decompensation and an increase in the risk of a fatal adverse event compared to those with less advanced liver disease.
U bolesnika s niskim početnim vrijednostima albumina (≤ 35 g/L) ili MELD indeksom ≥ 10 na početku liječenja, rizik od jetrene dekompenzacije bio je tri puta veći uz povećanje rizika pojave po život opasnog štetnog događaja u usporedbi s onima koji su imali manje uznapredovalu bolest jetre.
In patients with low albumin levels (≤ 35 g/L) or MELD score ≥ 10 at baseline, there was a three-fold greater risk of hepatic decompensation and an increase in the risk of a fatal adverse event compared to those with less advanced liver disease.
U bolesnika s niskim početnim vrijednostima albumina (≤ 35 g/L) ili MELD indeksom ≥ 10, zamijećen je tri puta veći rizik od jetrene dekompenzacije i povećanje rizika od letalnih štetnih događaja u usporedbi s bolesnicima s manje uznapredovalom jetrenom bolešću.
In patients with low complement levels, normalization of C3 and C4 was observed by Week 52 in 38% and 44% of patients receiving Benlysta and in 17% and 19% of patients receiving placebo.
U bolesnika s niskom razinom komplementa, normalizacija razine C3 i C4 opažena je do 52. tjedna u 38% odnosno 44% bolesnika koji su primali lijek Benlysta, te u 17% odnosno 19% bolesnika koji su primali placebo.
In patients with lower risk myelodysplastic syndromes, 97 out of 148 patients (66%) taking 10 mg Revlimid in the first study did not need a blood transfusion for at least 56 days.
U bolesnika sa nižim rizikom od mijelodisplastičnih sindroma, 97 od 148 bolesnika (66 %) koji su uzimali 10 mg lijeka Revlimid u prvom ispitivanju nije trebalo transfuziju krvi najmanje 56 dana.
In patients with lymphoid blast phase CML treated with the 140 mg once daily regimen, the median duration of MaHR was 5 months, the median PFS was 5 months, and the median overall survival was 11 months.
U bolesnika s KML u limfoidnoj blastnoj krizi liječenih dozom od 140 mg jedanput dnevno, medijan trajanja MaHR iznosio je 5 mjeseci, medijan PFS 5 mjeseci, a medijan ukupnog preživljenja 11 mjeseci.
In patients with macular oedema related to diabetes, who had not previously responded to, or were unsuitable for, other types of treatment, there was an average improvement in BCVA over both studies of 3.2 letters after Ozurdex 700 micrograms, compared with 1.5 letters after sham treatment
U bolesnika s makularnim edemom povezanim s dijabetesom koji nisu prethodno reagirali na druge terapije ili one za njih nisu bile prikladne, postojalo je prosječno poboljšanje u BCVA tijekom oba ispitivanja od 3,2 znaka nakon doze Ozurdexa od 700 mikrograma, u usporedbi sa 1,5 znakova nakon lažnog liječenja.
In patients with marked volume- and/or salt-depletion (e.g. patients with vomiting, diarrhoea or taking high doses of diuretics) symptomatic hypotension could occur after initiation of treatment with Edarbi.
Bolesnici s izrazito smanjenim volumenom i/ili nedostatkom elektrolita (npr. bolesnika koji povraćaju, imaju proljev ili uzimaju visoke doze diuretika) u početku liječenja Edarbijem mogu razviti simptomatsku hipotenziju.
In patients with marked volume- and/or salt-depletion (e.g. patients with vomiting, diarrhoea or taking high doses of diuretics) symptomatic hypotension could occur after initiation of treatment with Ipreziv.
Bolesnici s izrazito smanjenim volumenom i/ili nedostatkom elektrolita (npr. bolesnika koji povraćaju, imaju proljev ili uzimaju visoke doze diuretika) u početku liječenja Iprezivom mogu razviti simptomatsku hipotenziju.
In patients with MCL (study LYM-3002), the incidence of herpes zoster infection was 6.7% in the BR- CAP arm and 1.2% in the R-CHOP arm (see section 4.8).
U bolesnika s limfomom plaštenih stanica (ispitivanje LYM-3002), incidencija infekcije virusom herpes zoster bila je 6,7% u BR-CAP skupini i 1,2% u R-CHOP skupini (vidjeti dio 4.8).
In patients with MCL (study LYM-3002), there was a higher incidence (56.7% versus 5.8%) of Grade ≥ 3 thrombocytopenia in the bortezomib treatment group (BR-CAP) as compared to the non-bortezomib treatment group (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]).
U bolesnika s limfomom plaštenih stanica (isptivanje LYM-3002), postojala je viša incidencija (56,7% naspram 5,8%) trombocitopenije stupnja ≥ 3 u skupini liječenoj bortezomibom (BR-CAP), u usporedbi sa skupinom koja nije liječena bortezomibom (rituksimab, ciklofosfamid, doksorubicin, vinkristin i prednizon [R-CHOP]).
In patients with MCL (study LYM-3002), there was a higher incidence (56.7% versus 5.8%) of Grade ≥ 3 thrombocytopenia in the bortezomib treatment group (BzmbR-CAP) as compared to the non-bortezomib treatment group (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]).
U bolesnika s limfomom plaštenih stanica (isptivanje LYM-3002), postojala je viša incidencija (56,7 % naspram 5,8 %) trombocitopenije stupnja ≥ 3 u skupini liječenoj bortezomibom (BzmbR- CAP) u usporedbi sa skupinom koja nije liječena bortezomibom (rituksimab, ciklofosfamid, doksorubicin, vinkristin i prednizon [R-CHOP]).
In patients with MCL (study LYM-3002), there was a higher incidence (56.7% versus 5.8%) of Grade ≥ 3 thrombocytopenia in the bortezomib treatment group (BzR-CAP) as compared to the non-bortezomib treatment group (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]).
U bolesnika s limfomom plaštenih stanica (isptivanje LYM-3002), postojala je viša incidencija (56,7% naspram 5,8%) trombocitopenije stupnja ≥ 3 u skupini liječenoj bortezomibom (BzR-CAP) u usporedbi sa skupinom koja nije liječena bortezomibom (rituksimab, ciklofosfamid, doksorubicin, vinkristin i prednizon [R-CHOP]).
In patients with MCL (study LYM-3002), there was a higher incidence (56.7% versus 5.8%) of Grade ≥ 3 thrombocytopenia in the VELCADE treatment group (VcR-CAP) as compared to the non-VELCADE treatment group (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]).
U bolesnika s limfomom plaštenih stanica (isptivanje LYM-3002), postojala je viša incidencija (56,7% naspram 5,8%) trombocitopenije stupnja ≥ 3 u skupini liječenoj VELCADEom (VcR-CAP) u usporedbi sa skupinom koja nije liječena VELCADEom (rituksimab, ciklofosfamid, doksorubicin, vinkristin i prednizon [R-CHOP]).
In patients with MCL (study LYM-3002), there was a higher incidence (56.7% versus 5.8%) of Grade ≥ 3 thrombocytopenia in the VELCADE treatment group (VcR-CAP) as compared to the non-VELCADE treatment group (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]).
U bolesnika s limfomom plaštenih stanica (isptivanje LYM-3002), postojala je viša incidencija (56,7% naspram 5,8%) trombocitopenije stupnja ≥ 3 u skupini liječenoj VELCADEom (VcR-CAP), u usporedbi sa skupinom koja nije liječena VELCADEom (rituksimab, ciklofosfamid, doksorubicin, vinkristin i prednizon [R-CHOP]).
In patients with mild hepatic impairment (Child Pugh A), the recommended dose of Ofev is 100 mg twice daily approximately 12 hours apart.
U bolesnika s blagim oštećenjem funkcije jetre (Child Pugh A) preporučena doza Ofeva je 100 mg dvaput dnevno u razmaku od približno 12 sati.
In patients with mild hepatic impairment (Child-Pugh A), the mean AUC and Cmax increased 17% and 22% respectively, compared to healthy control subjects.
U bolesnika s blagim oštećenjem funkcije jetre (Child-Pugh A) srednja vrijednost AUC-a bila je povećana za 17%, a Cmax za 22% u usporedbi s onima u zdravih kontrolnih ispitanika.
In patients with mild hepatic impairment (Child-Pugh A), the mean AUC and Cmax increased 17% and 22% respectively, compared to healthy control subjects.
U bolesnika s blagim oštećenjem jetrene funkcije (Child-Pugh A) srednja vrijednost AUC-a bila je povećana za 17%, a Cmax za 22% u usporedbi s onima u zdravih kontrolnih ispitanika.
In patients with mild hepatic impairment (Child-Pugh A), the mean AUC and Cmax increased by 17% and 22% respectively, compared to healthy control subjects.
U bolesnika s blagim oštećenjem funkcije jetre (Child-Pugh A) srednja vrijednost AUC bila je povećana za 17%, a Cmax za 22% u usporedbi s onima u zdravih kontrolnih ispitanika.
In patients with mild or moderate renal impairment (creatinine clearance  30–80 ml/min) compared to those with normal renal function (creatinine clearance > 80 ml/min), the most commonly reported events and their placebo-corrected frequencies included: constipation (8% versus 4%), dizziness (7% versus 5%), and nausea (4% versus 2%).
Kod bolesnika s blago ili umjereno oštećenom funkcijom bubrega (klirens kreatinina  30–80 ml/min) u usporedbi s bolesnicima s normalnom funkcijom bubrega (klirens kreatinina > 80 ml/min), najčešće zabilježene nuspojave i njihove učestalosti korigirane u odnosu na placebo uključivale su: konstipaciju (8% u odnosu na 4%), omaglicu (7% u odnosu na 5%) i mučninu (4% u odnosu na 2%).
In patients with mild or moderate renal impairment (GFR 30 – 80 ml/min), Cmax and AUC of the active metabolite increased up to 1.5 and 1.8-fold, respectively, as compared to healthy subjects.
U bolesnika s blagim ili umjerenim oštećenjem funkcije bubrega (GFR 30 – 80 ml/min), Cmax djelatnog metabolita povećala se do 1,5 puta, a AUC do 1,8 puta u usporedbi s onima u zdravih ispitanika.
In patients with mild or moderate renal impairment a loading dose of 200 mg may be considered but further dose titration (>200 mg daily) should be performed with caution.
Kod bolesnika s blagim ili umjerenim oštećenjem bubrega može se razmotriti mogućnost udarne doze od 200 mg, ali daljnju titraciju doze (>200 mg dnevno) treba provoditi s oprezom.
In patients with mild or moderate renal impairment a loading dose of 200 mg may be considered, but further dose titration (>200 mg daily) should be performed with caution.
Kod bolesnika s blagim ili umjerenim oštećenjem bubrega može se razmotriti mogućnost udarne doze od 200 mg, ali daljnju titraciju doze (>200 mg dnevno) treba provoditi s oprezom.
In patients with mild renal impairment (CrCL > 50 – 80 mL/min), the recommended dose is 60 mg Lixiana once daily.
Za bolesnike s blagim oštećenjem funkcije bubrega (CrCL > 50 – 80 ml/min), preporučena doza Lixiane je 60 mg jedanput na dan.
In patients with mild renal impairment (creatinine clearance 51 to 80 ml/min), AUC increased by 24% and Cmax by 15% compared with patients with normal renal function.
Kod bolesnica s blagim oštećenjem bubrežne funkcije (klirens kreatinina 51 do 80 ml/min), AUC se povećao za 24% i Cmax za 15% u usporedbi sa bolesnicama s normalnom bubrežnom funkcijom.
In patients with mild renal impairment (estimated creatinine clearance [CrCL] > 50 mL/min), no dose adjustment is necessary, see section 5.2).
U bolesnika s blagim oštećenjem funkcije bubrega (procijenjeni klirens kreatinina [CrCl] >50 ml/min) nije potrebno prilagođavati dozu (vidjeti dio 5.2).